GLP-1 medications work by interacting with natural appetite-regulating pathways, which may help some patients feel satisfied sooner and manage portion sizes more comfortably when paired with lifestyle changes
One-carbon metabolism in neurodevelopmental disorders: Using broad-based nutraceutics to treat cognitive deficits in complex spectrum disorders
July 2024: Roche reported early clinical data for CT-996, its once-daily oral GLP-1 receptor agonist, showing clinically meaningful weight loss after four weeks and supporting further development in obesity and type 2 diabetes
Lu SC (2020) Dysregulation of glutathione synthesis in liver disease
GLP-1 agonists are gaining popularity quickly due to their promising effects in managing type 2 diabetes as well as promoting weight loss
FDA panel narrowly backs peptide drug touted by Joe Rogan and other influencers WASHINGTON (AP) A panel of federal health advisers on Thursday narrowly recommended easing access to several peptides popular with wellness influencers and celebrities, despite warnings from government scientists that the chemicals havent been shown to be safe or effective
